Medical Economics Pulse Podcast Por Medical Economics Pulse arte de portada

Medical Economics Pulse

Medical Economics Pulse

De: Medical Economics Pulse
Escúchala gratis

Acerca de esta escucha

 Medical Economics Pulse is a quick-hitting news podcast that keeps physicians in the know. Each episode lasts only a few minutes and delivers concise updates on the most important developments affecting your practice, your bottom line, and the broader health care landscape, delivered to you by the Medical Economics staff editors. From policy changes and reimbursement news to emerging trends and technologies, we distill the most critical headlines into an easy-to-digest format. Stay informed, save time, and gain the insights you need to navigate the business of medicine — all in under five minutes. Enfermedades Físicas Hygiene & Healthy Living Política y Gobierno
Episodios
  • 19: The Weekly Dose from Patient Care: How Medicaid Policies Impact Postpartum Depression Care

    19: The Weekly Dose from Patient Care: How Medicaid Policies Impact Postpartum Depression Care
    May 22 2025
    In this episode of The Weekly Dose, Patient Care editors speaks with Elizabeth Mollard, PhD, about new research she presented at the 2025 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting that highlighted how Medicaid policy directly impacts postpartum depression (PPD) diagnosis rates. Drawing on national data, Mollard explains that more generous Medicaid coverage—especially extended postpartum eligibility—leads to more frequent diagnoses of PPD, a finding that underscores the critical importance of access to care. The conversation covers clinical implications, the effects of the COVID-19-era Medicaid expansion and wind-down, and practical recommendations for clinicians and policymakers to improve mental health outcomes for postpartum patients.

    Key Points:

    • More robust Medicaid coverage leads to higher rates of PPD diagnosis.
      This is not indicative of higher prevalence, but rather of improved access and identification of women in need of care.

    • Medicaid policy changes during the COVID-19 pandemic offer a natural experiment.
      When postpartum Medicaid coverage was expanded nationally, diagnosis rates rose. After the expansion ended, diagnoses dropped—likely due to decreased access, not decreased incidence.

    • Universal screening should be standard clinical practice.
      Mollard recommends screening beyond the six-week postpartum visit and ensuring continuity of care for those who screen positive.

    • Medicaid must support a full range of postpartum mental health services.
      Coverage should include not only screening, but also counseling, medications like zuranolone, and extended eligibility through 12 months postpartum.

    • Policy gaps leave many women uninsured at a vulnerable time.
      Many working women earn too much to qualify for Medicaid but too little to afford private insurance, making extended postpartum coverage essential to reduce disparities and prevent worsening mental health outcomes.
    Más Menos
    5 m
  • 18: Weekly Dose from Patient Care Online: New Findings on BV, Atopic Dermatitis, Colorectal Cancer, and More

    18: Weekly Dose from Patient Care Online: New Findings on BV, Atopic Dermatitis, Colorectal Cancer, and More
    May 7 2025
    In this episode of Weekly Dose, we dive into the most impactful clinical research from the past week on Patient Care, covering key studies across multiple specialties. We begin with a study on the treatment of bacterial vaginosis, highlighting the significant impact of antimicrobial therapy for male partners in reducing recurrence rates. Next, we explore a meta-analysis on the use of dupilumab in treating atopic dermatitis in children, showcasing its effectiveness in reducing disease severity and pruritus. We also cover a groundbreaking study on colorectal cancer risk models for adults aged under 45 years, introducing new ways to personalize screening strategies.

    Additionally, we discuss the EKSTROM trial, which presents data on colchicine’s role in stabilizing coronary plaque and reducing cardiovascular risk. Finally, we look at the FDA’s approval of dupilumab for chronic spontaneous urticaria, offering new hope for patients with persistent symptoms despite antihistamine treatment.
    Más Menos
    5 m
  • 17: Medical Economics Pulse, April 4, 2025: CMS Director Oz, autoinjector factory in South Carolina, rural independent practice declines

    17: Medical Economics Pulse, April 4, 2025: CMS Director Oz, autoinjector factory in South Carolina, rural independent practice declines
    Apr 4 2025
    Hello and welcome to Medical Economics Pulse, a quick-hitting news podcast that keeps busy physicians in the know. We offer concise updates on the most important developments affecting your practice, your bottom line, and the broader health care landscape, delivered to you by our editorial team at Medical Economics.

    It’s Friday, April 4, 2025, and here are today’s headlines:

    Dr. Mehmet Oz, a cardiothoracic surgeon and former television host, has been confirmed by the U.S. Senate as the new administrator of the Centers for Medicare & Medicaid Services (CMS), succeeding Chiquita Brooks-LaSure. While some applaud his communication skills and medical background, others voice strong concern over his history of promoting non-evidence-based treatments and his alignment with controversial policy positions. Pharmacy stakeholders, like the National Association of Chain Drug Stores, see Oz’s appointment as an opportunity to push for reform of pharmacy benefit managers and chronic disease prevention, while critics warn of potential threats to Medicare, Medicaid, and the Affordable Care Act.

    On the innovation front, there’s a big move in South Carolina. SHL Medical has officially opened a state-of-the-art manufacturing facility in North Charleston. The site will specialize in advanced drug delivery systems, including autoinjectors, a growing market driven by the surge in biologics. The new 360,000-square-foot facility, representing a $220 million investment, is designed to manufacture SHL Medical’s autoinjectors used in the treatment of endocrine and metabolic disorders — including GLP-1 therapies — as well as dermatology, musculoskeletal diseases, and other therapeutic areas. This facility also signals a reshoring trend — bringing manufacturing closer to U.S. health care markets, reducing supply chain delays, and potentially improving access and cost-efficiency.

    Finally, the independent physician practice is quietly vanishing from the heart of rural America. According to a recent report from the Physicians Advocacy Institute (PAI), rural areas are seeing a steady decline in small, physician-owned practices. What’s driving this? Financial strain, staffing shortages, and increasing administrative burdens have forced many doctors to either retire early or join larger health systems. For communities already grappling with limited access to care, this shift widens the health care gap, particularly in primary care and preventive services. As this situation gets worse, the medical community may turn to advocacy and push for policies that preserve autonomy and access in these underserved areas.

    And that’s it for today’s Medical Economics Pulse. Be sure to subscribe for new episodes, and read more health business news and expert content at MedicalEconomics.com. Be sure to subscribe to our premiere podcast, “Off the Chart, A Business of Medicine Podcast,” which features lively and informative conversations with health care experts, opinion leaders, and practicing physicians about the challenges facing doctors and medical practices.

    Thanks for tuning in.
    Más Menos
    3 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones